Literature DB >> 27671060

Crystal Structure of the Pseudomonas aeruginosa BEL-1 Extended-Spectrum β-Lactamase and Its Complexes with Moxalactam and Imipenem.

Cecilia Pozzi1, Filomena De Luca2, Manuela Benvenuti1, Laurent Poirel3,4, Patrice Nordmann3,4, Gian Maria Rossolini2,5,6, Stefano Mangani7,8, Jean-Denis Docquier9.   

Abstract

BEL-1 is an acquired class A extended-spectrum β-lactamase (ESBL) found in Pseudomonas aeruginosa clinical isolates from Belgium which is divergent from other ESBLs (maximum identity of 54% with GES-type enzymes). This enzyme is efficiently inhibited by clavulanate, imipenem, and moxalactam. Crystals of BEL-1 were obtained at pH 5.6, and the structure of native BEL-1 was determined from orthorhombic and monoclinic crystal forms at 1.60-Å and 1.48-Å resolution, respectively. By soaking native BEL-1 crystals, complexes with imipenem (monoclinic form, 1.79-Å resolution) and moxalactam (orthorhombic form, 1.85-Å resolution) were also obtained. In the acyl-enzyme complexes, imipenem and moxalactam differ by the position of the α-substituent and of the carbonyl oxygen (in or out of the oxyanion hole). More surprisingly, the Ω-loop, which includes the catalytically relevant residue Glu166, was found in different conformations in the various subunits, resulting in the Glu166 side chain being rotated out of the active site or even in displacement of its Cα atom up to approximately 10 Å. A BEL-1 variant showing the single Leu162Phe substitution (BEL-2) confers a higher level of resistance to CAZ, CTX, and FEP and shows significantly lower Km values than BEL-1, especially with oxyiminocephalosporins. BEL-1 Leu162 is located at the beginning of the Ω-loop and is surrounded by Phe72, Leu139, and Leu148 (contact distances, 3.5 to 3.9 Å). This small hydrophobic cavity could not reasonably accommodate the bulkier Phe162 found in BEL-2 without altering neighboring residues or the Ω-loop itself, thus likely causing an important alteration of the enzyme kinetic properties.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27671060      PMCID: PMC5118998          DOI: 10.1128/AAC.00936-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  Defining an extended-spectrum beta-lactamase.

Authors:  D M Livermore
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

2.  Stability of TEM beta-lactamase mutants hydrolyzing third generation cephalosporins.

Authors:  X Raquet; M Vanhove; J Lamotte-Brasseur; S Goussard; P Courvalin; J M Frère
Journal:  Proteins       Date:  1995-09

3.  Interactions between active-site-serine beta-lactamases and compounds bearing a methoxy side chain on the alpha-face of the beta-lactam ring: kinetic and molecular modelling studies.

Authors:  A Matagne; J Lamotte-Brasseur; G Dive; J R Knox; J M Frère
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

4.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

5.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Mechanism of acyl transfer by the class A serine beta-lactamase of Streptomyces albus G.

Authors:  J Lamotte-Brasseur; G Dive; O Dideberg; P Charlier; J M Frère; J M Ghuysen
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

8.  1H NMR study of degradation mechanisms of oxacephem derivatives with various 3'-substituents in alkaline solution.

Authors:  J Nishikawa; F Watanabe; M Shudou; Y Terui; M Narisada
Journal:  J Med Chem       Date:  1987-03       Impact factor: 7.446

9.  Crystal structure of the extended-spectrum β-lactamase PER-2 and insights into the role of specific residues in the interaction with β-lactams and β-lactamase inhibitors.

Authors:  Melina Ruggiero; Frédéric Kerff; Raphaël Herman; Frédéric Sapunaric; Moreno Galleni; Gabriel Gutkind; Paulette Charlier; Eric Sauvage; Pablo Power
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

Review 10.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14
View more
  4 in total

1.  Influence of the α-Methoxy Group on the Reaction of Temocillin with Pseudomonas aeruginosa PBP3 and CTX-M-14 β-Lactamase.

Authors:  Michael D Sacco; Kyle G Kroeck; M Trent Kemp; Xiujun Zhang; Logan D Andrews; Yu Chen
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Local Interactions with the Glu166 Base and the Conformation of an Active Site Loop Play Key Roles in Carbapenem Hydrolysis by the KPC-2 β-lactamase.

Authors:  Ian M Furey; Shrenik C Mehta; Banumathi Sankaran; Liya Hu; B V Venkataram Prasad; Timothy Palzkill
Journal:  J Biol Chem       Date:  2021-05-19       Impact factor: 5.157

3.  Crystal structures of the elusive Rhizobium etli L-asparaginase reveal a peculiar active site.

Authors:  Joanna I Loch; Barbara Imiolczyk; Joanna Sliwiak; Anna Wantuch; Magdalena Bejger; Miroslaw Gilski; Mariusz Jaskolski
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

4.  Mechanistic Insights into β-Lactamase-Catalysed Carbapenem Degradation Through Product Characterisation.

Authors:  Christopher T Lohans; Emily I Freeman; Emma van Groesen; Catherine L Tooke; Philip Hinchliffe; James Spencer; Jürgen Brem; Christopher J Schofield
Journal:  Sci Rep       Date:  2019-09-20       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.